Exelxis - Chart of the 16 new highs and up

Exelixis (EXEL) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend spotter buy signal, a Weighted Alpha of 243.90+ and gained 277.72% in the last 6 month.


The Chart of the Day is Exelixis (EXEL) and is a repeat from 8/22 but has a chart that can't be ignored.  I found the biopharmaceutical stock by using Barchart to sort the Russell 3000 Index stocks first by the most frequent number of new highs in the last month, then again by technical buy signals of 80% or more.  Since the Trend spotter signaled a buy on 4/6 the stock gained 243.05%.

Exelixis, Inc. (EXEL) is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.

 

The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

• 96% technical buy signals
• Trend Spotter buy signals
• Above its 20, 50 and 100 day moving averages
• 16 new highs and 39.23% in the last month
• Relative Strength Index 86.09%
• Technical support level at 14.60
• Recently traded at 15.30 with a 50 day moving average of 11.13

Fundamental factors:

• Market Cap $3.50 billion
• Revenue expected to grow 312.80% this year and another 90.10% next year
• Earnings estimated to increase 23.50% this year and an additional 83.90% next year
• Wall Street analysts issued 4 strong buy and 1 hold
• The individual investors following the stock on Motley Fool voted 2469 to 99 that the stock will beat the market
• Of the Wall Street professional featured on Motley Fool they have buy signals 8 to 0

Exelixis - Chart of the Day

Exelixis (EXEL) is the Barchart Chart of the Day.  The biomedical company has a Trend Spotter buy signal, a Weighted Alpha of 140.20+ and gained 179.17% in the last 6 months.


The Chart of the Day belongs to Exelixis (EXEL).  I found the biomedical stock by using Barchart to sort the Russell 3000 Index stocks first by the highest Weighted Alpha then again by technical buy signals of 80% or more.  Since the Trend Spotter signaled a buy on 4/6 the stock gained 155.38%.

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.

The status of Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

• 80% technical buy signals
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 8 new highs and up 31.22% in the last month
• Relative Strength Index 76.00%
• Technical support level at 10.67
• Recently traded at 11.35 with a 5 day moving average of 8.88

Fundamental factors:

• Market Cap $2.60 billion
• Revenue expected to grow 244.20% this year and another 104.00% next year
• Earnings estimated to increase 12.30% this year and another 67.60% next year
• Wall Street analysts issued 4 strong buy and 1 hold recommendation on the stock

MORNING CALL 1/5

MORNING CALL

Tuesday, January 5th, 2016View Older Reports

Everything you need to know about the markets in one free daily newsletter.

E-mail:  

You will also receive a free subscription to the Barchart family of newsletters.

OVERNIGHT MARKETS AND NEWS

March E-mini S&Ps (ESH16 -0.61%) are down -0.66% and European stocks are down -0.57% at a 3-month low as China's Shanghai Composite extended Monday's sell-off and fell to a new 2-1/2 month low. Deflation concerns also hurt European equities and knocked EUR/USD down to a 1-month low after Eurozone Dec CPI rose less than expected. Asian stocks settled mostly lower: Japan -0.42%, Hong Kong -0.65%, China -0.26%, Taiwan -0.48%, Australia -1.63%, Singapore -0.06%, South Korea +0.64%, India -0.17%. China's Shanghai Composite recovered from its worst levels in late trading after China moved to support the market with state-controlled funds buying equities and after people familiar with the matter said that regulators will extend the selling ban by major investors beyond Friday's expiration date.

The dollar index (DXY00 +0.41%) is up +0.41% at a 2-week high. EUR/USD (^EURUSD) is down -0.64% at a 1-month low after weaker-than-expected Eurozone Dec consumer price data fueled speculation the ECB may need to expand QE. USD/JPY (^USDJPY) is down -0.39%.

Mar T-note prices (ZNH16 +0.14%) are up +6 ticks.

The Eurozone Dec CPI estimate rose +0.2% y/y, less than expectations of +0.3% y/y. The Dec core CPI rose +0.9% y/y, less than expectations of +1.0% y/y.

U.S. STOCK PREVIEW

Key U.S. news today includes: (1) (1) Dec New York ISM (Nov -5.1 to 60.7), and (2) Dec total vehicle sales (expected 18.00 million, Nov 18.05 million) and Dec domestic vehicle sales (expected 14.20 million, Nov 13.99 million).

None of Russell 3000 companies report earnings today.

U.S. IPO's scheduled to price today: none.

Equity conferences this week: J.P. Morgan Tech Forum on Tue, Goldman Sachs Health Care CEO Unscripted Conference on Tue, Goldman Sachs Global Energy Conference on Wed, and Citi Global Internet, Media & Telecommunications Conference on Wed-Thu.

OVERNIGHT U.S. STOCK MOVERS

Nordstrom (JWN +0.64%) was downgraded to 'Neutral' from 'Buy' at Citigroup.

Eli Lilly (LLY -1.65%) may move lower at the start of trading today after it lowered guidance on fiscal 2016 EPS to $3.45-$3.55, below consensus of $3.65.

JC Penney (JCP +4.65%) was upgraded to 'Neutral' from 'Sell' at Citigroup.

First Solar (FSLR +1.11%) rose over 2% in pre-market trading after it was upgraded to 'Buy' from 'Neutral at Goldman Sachs.

SolarEdge Technologies (SEDG -0.60%) rose nearly 2 % in pre-market trading after the stock was added to the 'Conviction Buy' list at Goldman Sachs.

Fresh Del Monte Produce (FDP -1.93%) was rated a new 'Buy' at Wunderlich Securities with a 12-month price target of $45.

DDR Corp. (DDR -1.72%) lowered guidance on its 2016 operating FFO to $1.19-$1.25 a share from a previous FFO estimate of $1.26.

Intercontinental Excahnge (ICE -1.90%) was reinstated a 'Buy' and added to the 'Conviction Buy' list at Goldman Sachs with a price target of $310.

General Electric reported a 33% stake in NeoGenomics (NEO -3.94%) .

Smith & Wesson (SWHC +5.91%) rose over 4% in after-hours trading after it raised guidance on Q3 adjusted EPS to 39 cents-41 cents, higher than consensus of 29 cents, and then raised guidance on fiscal 2016 adjusted EPS to $1.36-$1.41 from a prior estimate of $1.26-$1.31.

Gilead (GILD -3.14%) climbed +0.4% in after-hours trading after its fixed-dose combination of Sovaldi and velpatasvir was granted priority review by the U.S. FDA for the treatment of Hepatitis C.

Acceleron (XLRN -8.00%) fell over 2% in after-hours trading after the company proposed a $150 million offering of common stock.

Progressive Waste Solutions (BIN -1.44%) jumped 6% in after-hours trading after it said it was exploring the prospects of a potential sale of the company.

Exelixis (EXEL -2.66%) climbed over 8% in after-hours trading after a Phase 3 study showed its Cabozantinib drug shrank kidney cancer tumors in 75% of patients tested.

MARKET COMMENTS

Mar E-mini S&Ps (ESH16 -0.61%) this morning are down -13.25 points (-0.66%). Monday's closes: S&P 500 -1.53%, Dow Jones -1.58%, Nasdaq-2.08%. The S&P 500 on Monday slumped to a 2-3/4 month low and closed sharply lower on negative carryover from a -6.86% plunge in China's Shanghai Composite tied to the China Dec manufacturing PMI report of +0.1 to 49.7, weaker than expectations of +0.2 to 49.8, and the unexpected -0.4point drop in the Dec ISM U.S. manufacturing index to a 6-1/2 year low of 48.2, weaker than expectations of +0.4 to 49.0. Stocks were also undercut by the unexpected -0.4% decline in U.S. Nov construction spending, weaker than expectations of +0.6% and the biggest decline in 17 months.

Mar 10-year T-notes (ZNH16 +0.14%) this morning are up +6 ticks. Monday's closes: TYH6 +8.00, FVH6 +4.75. Mar T-notes on Monday rose to a 1-1/2 week high and closed higher on the plunge in global stocks, which boosted the safe-haven demand for T-notes. T-notes were also boosted by U.S. growth concerns after the Dec ISM U.S. manufacturing index fell to a 6-1/2 year low.

The dollar index (DXY00 +0.41%) this morning is up +0.409 (+0.41%) at a 2-week high. EUR/USD (^EURUSD) is down -0.0069 (-0.64%) to a 1-month low. USD/JPY (^USDJPY) is down -0.46 (-0.39%). Monday's closes: Dollar Index +0.186 (+0.19%), EUR/USD -0.0025 (-0.23%), USD/JPY -1.11(-0.92%). The dollar index on Monday climbed to a 2-week high and settled higher on the plunge in EUR/USD to a 1-month low after German Dec CPI rose less than expected, which may prompt the ECB to boost stimulus measures. In addition, there was weakness in the Chinese yuan which tumbled to a 4-1/2 year low against the dollar on speculation that economic weakness in China may push the PBOC into expand its stimulus measures.

Feb crude oil (CLG16 -0.57%) this morning is unchanged and Feb gasoline (RBG16 +0.41%) is up +0.0132 (+1.02%). Monday's closes: CLG6 -0.16(-0.43%), RBG6 +0.0185 (+1.46%). Feb crude oil and gasoline on Monday both posted 2-week highs but settled mixed. Feb crude fell back from a 2-week high on a rally in the dollar index to a 2-week high and on global energy demand concerns after the China Dec manufacturing PMI contracted for a fifth month and the Dec ISM U.S. manufacturing index contracted by the most in 6-1/2 years. Crude oil prices found support on geopolitical concerns after Saudi Arabia cut diplomatic ties with Iran when demonstrators in Tehran attacked the Saudi embassy, and on increased refinery demand for gasoline after the crack spread climbed to a 1-1/2 week high.

GLOBAL EVENT CALENDAR01/05/2016

US	0945 ET	Dec New York ISM, Nov -5.1 to 60.7.
	n/a	Dec total vehicle sales expected 18.00 million, Nov 18.05 million. Dec domestic vehicle sales expected 14.20 million, Nov 13.99 million.
JPN	0000 ET	Japan Dec vehicle sales, Nov +0.3% y/y.
GER	0355 ET	German Dec unemployment change expected -8,000, Nov -13,000. Dec unemployment rate expected unch at 6.3%.
UK	0430 ET	UK Dec Markit/CIPS construction PMI expected +0.7 to 56.0, Nov 55.3.
EUR	0500 ET	Eurozone Dec CPI estimate expected +0.4% y/y, Nov +0.2% y/y. Dec core CPI expected +1.0% y/y, Nov +0.9% y/y.
CHI	2045 ET	China Dec Westpac-MNI consumer sentiment, Nov 113.1.

U.S. STOCK CALENDAR01/05/2016

Company	Ticker	Time	Event Description	Period	Estimate
Eli Lilly & Co	LLY US	9:00	Q4 2016 Guidance Call	Q4 2016
Ford Motor Co	F US	9:15	December 2015 Sales and Revenue Release	2015
Ford Motor Co	F US	10:00	December 2015 Sales and Revenue Call	2015
Delta Air Lines Inc	DAL US		December 2015 Sales and Revenue Release - Traffic Results	2015

Exelixis Inc - Chart of the Day

Exelixis (EXEL) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend Spotter buy signal, a Weighted Alpha of 219.00+ and gained 282.47% in the last year.


The Chart of the Day belongs to Exelixis (EXEL).  I found the biopharmaceutical stock by using Barchart to sort the Russell 3000 Index stocks first for the highest Weighted Alpha then again for technical buy signals of 80% or better.  Since the Trend Spotter signaled a buy on 8/27 the stock gained 8.05%.

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.

The status of Barchart's Opinion trading systems are listed below.  Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates.  The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report.

Barchart technical indicators:

• 96% Barchart technical buy signals
• 219.00+ Weighted Alpha
• Trend Spotter buy signal
• Above its 20, 50 and 100 day moving averages
• 4 new highs and up 15.01% in the last month
• Relative Strength Index 65.52%
• Bar hart computes a technical support level at 5.97
• Recently traded at 6.51 with a 50 day moving average of 5.59

Fundamental factors:

• Market Cap $1.45 billion
• Revenue projected to grow 41.30% this year and another 130.90% next year
• Earnings are estimated to increase 41.30% this year and an additional 11.10% next year
• Wall Street analysts issued 2 strong buy and 3 hold recommendations on the stock
• The individual investors on Motley Fool voted 2,482 to 97 that the stock will beat the market

The 20-50 Day MACD Oscillator has been a reliable technical trading strategy for this stock/

A play in genetic research

I'm fascinated by genetic research and especially the National Geographic Genome project.  I can't get enough of this stuff and here is a company right in the middle of it all: Exelixs ( EXEL) and it's making money at it too.  Their big discovery is XL184 a promising compound for the treatment of oncological cancers

Exelixis Inc. (EXEL) is a leader in the fields of model system genetics and comparative genomics. These fields involve the systematic study of simple organisms, such as fruit flies, nematodes, mice, zebra fish and simple plants, to rapidly and efficiently determine gene function and establish its commercial utility in humans and other commercially important biological systems. The proprietary technologies provide a rapid, efficient and cost-effective way to move beyond DNA sequence data to understand the function of genes and the proteins that they encode.

Technical Factors:

• 100% Barchart technical buy signal
• Trend Spotter (tm) buy signal
• 10 new highs and up 43.74% in the last month
• Relative strength Index is 79.98% and climbing
• Trades around 22.40 with a 50 day moving average of 9.01

Fundamental Factors:

• Wall Street brokerage analysts have published 4 buy and 3 hold reports
• Revenue is expected to increase by 5.30% next year
• Earnings are projected to increase by 22.40% this year and 22.70% next year

Investor sentiment:

• A surprising number of general investors have discovered this small stock
• On Motley Fool CAPS members vote 2,387 to 96 that the stock will out perform the market
• The more experienced All Stars agree 915 to 21
• Fool notes that Wall Street columnists have written 4 positive articles about the company

Jim Van Meerten is an analyst for  Marketocracy Capital Management.  He shares his knowledge and experience from over 40 years of investing in stocks, mutual funds and ETFs on Barchart.com  in his daily blog -- Barchart Portfolio Blogs.

Through Marketocracy Capital Management  you can have a Separately Managed Account that mirrors his Barchart Van Meerten New High model portfolio.